|
| Status |
Public on Sep 30, 2017 |
| Title |
ChIPSeq data from melanoma cancer cell line CHL-1 after Bromodomain and extra terminal (Bet) domain inhibitor treatment |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
Bromodomain and extra terminal domain (BET) inhibition reduces occupancy of BET-family proteins at promoter and enhancer sites finally leading to genome wide changes in gene transcription.
We used ChIPSeq profiling to investigate genome wide changes in promoter and enhancer occupancy induced by BET inhibitors BAY 1238097 and OTX-015, respectively.
|
| |
|
| Overall design |
CHL-1 cells were treated with BAY 1238097 or OTX-015, potent and selective Bromodomain and extra terminal domain (BET) inhibitors, before chromatin immunoprecipitation using antibodies directed against BRD4 and acetylated H3K27.
|
| |
|
| Contributor(s) |
Gelato K, Klingbeil O, Lesche R, Haendler B |
| Citation(s) |
28991225 |
| |
| Submission date |
Mar 01, 2017 |
| Last update date |
May 15, 2019 |
| Contact name |
Ralf Lesche |
| E-mail(s) |
ralf.lesche@bayer.com
|
| Organization name |
Bayer Pharma AG
|
| Street address |
Muellerstr 178
|
| City |
Berlin |
| ZIP/Postal code |
13342 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (18)
|
|
| Relations |
| BioProject |
PRJNA377564 |
| SRA |
SRP100943 |
Less...
More...